Rectal Neoplasms
Conditions
Brief summary
Primary objective: \- To evaluate the rate of responses to neoadjuvant therapy + radiotherapy Secondary objective: \- tolerability (toxicity) and time to progression
Interventions
DRUGOXALIPLATIN
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. Main criteria are listed hereafter: Inclusion Criteria: * Patients with measurable, histologically proven rectal cancer. * No history of previous malignancy but adequately treated skin / cervical cancer. * Adequate haematological, renal and liver function.
Exclusion criteria
* No cardiopulmonary insufficiency or coronary disease. No sensory neuropathy prior to study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumour response | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free and Overall survival ; Adverse events | — |
Outcome results
None listed